NCT02299050View on ClinicalTrials.gov

Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Type 2 Diabetes
Interventions
DRUG

Cycloset

Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR

Trial Locations (1)

78229

University of Texas Health Science Center, San Antonio

Sponsors

Collaborators (1)

VeroScience
All Listed Sponsors
collaborator

VeroScience

INDUSTRY

lead

The University of Texas Health Science Center at San Antonio

OTHER